Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company that develops and commercializes therapies for patients with unmet medical needs, with a primary focus on endocrinology and rare diseases. Headquartered in Hellerup, Denmark and founded in 2006, the company uses its TransCon technology platform to modify existing drug molecules to improve dosing convenience and therapeutic profile. Ascendis Pharma A/S currently markets SKYTROFA for pediatric patients with growth hormone deficiency and YORVIPATH, a once-daily subcutaneous injection for adults with chronic hypoparathyroidism. Beyond its commercial products, the company is advancing a pipeline of endocrinology rare disease candidates in clinical development and pursuing oncology programs built on the same TransCon approach. Through subsidiaries in Europe and the United States, Ascendis Pharma A/S operates on a global scale, serving specialists in endocrinology and related fields. Its role in the market centers on bringing long-acting, clinically focused therapies to niche but medically significant patient populations.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Jan Moller Mikkelsen

Employees

1,017

Headquarters

Hellerup, Denmark

Website

ascendispharma.com